New Study Provides Comparative Analysis of 12 COVID-19 Vaccines
Photo: Novateur Ventures
A new study by Novateur Ventures provides a comparative analysis of twelve COVID-19 Vaccines that had initiated or announced the Phase III clinical trial stage by early November 2020. The study highlights the early successes, as well as the hurdles and barriers yet to be overcome for ending the global COVID-19 pandemic.
COVID-19 vaccines analyzed for the study
- messenger RNA - Moderna and Pfizer/BioNtech
- Viral Vector-based (non-replicating) Vaccines - Astra Zeneca/University of Oxford, CanSino Biologics, Gamaleya Research Institute, Johnson & Johnson/Janssen (J&J)
- Recombinant Protein-based Vaccines - Novavax and Medicago
- Inactivated Virus - Three Chinese conglomerates and ...